{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:45:44Z","timestamp":1791549944750,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T00:00:00Z","timestamp":1618012800000},"content-version":"am","delay-in-days":434,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.smim.2020.101392","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T17:56:03Z","timestamp":1578506163000},"page":"101392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Primary immunoprevention of adult onset cancers by vaccinating against retired tissue-specific self-proteins"],"prefix":"10.1016","volume":"47","author":[{"given":"Vincent K.","family":"Tuohy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suparna","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.smim.2020.101392_bib0005","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101392_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.smim.2020.101392_bib0015","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science."},{"key":"10.1016\/j.smim.2020.101392_bib0020","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Taiwan Childhood Hepatoma Study Group, Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children","volume":"336","author":"Chang","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101392_bib0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S0950268815002198","article-title":"Prophylactic HPV vaccination: past, present, and future","volume":"144","author":"Castle","year":"2016","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.smim.2020.101392_bib0030","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1016\/j.vaccine.2017.07.113","article-title":"Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: a literature review","volume":"36","author":"Maver","year":"2018","journal-title":"Vaccine."},{"key":"10.1016\/j.smim.2020.101392_bib0035","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1016\/j.vaccine.2011.09.012","article-title":"Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies","volume":"29","author":"Dalgleish","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.smim.2020.101392_bib0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coi.2015.05.004","article-title":"The role of active vaccination in cancer immunotherapy: lessons from clinical trials","volume":"35","author":"Kissick","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2020.101392_bib0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.15585\/mmwr.mm6805a5","article-title":"Advisory Committee on Immunization Practices. Recommended immunization schedule for adults aged 19 years or older - United States, MMWR","volume":"68","author":"Kim","year":"2019","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.smim.2020.101392_bib0050","unstructured":"The human \u03b1-lactalbumin gene, LALBA, UniProtKB\u2013P00709, https:\/\/www.uniprot.org\/uniprot\/P00709, (accessed September 27, 2019)."},{"key":"10.1016\/j.smim.2020.101392_bib0055","series-title":"Breast Cancer Facts & Figures 2017-2018","author":"American Cancer Society","year":"2017"},{"key":"10.1016\/j.smim.2020.101392_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.smim.2020.101392_bib0065","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1245\/s10434-014-4279-0","article-title":"The 2014 society of surgical oncology Susan G. Komen for the cure symposium: triple-negative breast cancer","volume":"22","author":"Newman","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.smim.2020.101392_bib0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8060056","article-title":"Targeted vaccination against human \u03b1-lactalbumin for Immunotherapy and primary immunoprevention of triple negative breast cancer","volume":"8","author":"Tuohy","year":"2016","journal-title":"Cancers. (Basel)."},{"key":"10.1016\/j.smim.2020.101392_bib0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ca.22165","article-title":"Anatomy of the human mammary gland: current status of knowledge","volume":"26","author":"Hassiotou","year":"2013","journal-title":"Clin. Anat."},{"key":"10.1016\/j.smim.2020.101392_bib0080","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1586\/14760584.2014.953063","article-title":"Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers","volume":"13","author":"Tuohy","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.smim.2020.101392_bib0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1043-2760(99)00155-1","article-title":"TGF-beta family members and gonadal development","volume":"10","author":"Josso","year":"1999","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.smim.2020.101392_bib0090","unstructured":"The human anti-M\u00fcllerian hormone receptor type II gene, AMHR2, UnitProtKB\u2013Q16671, https:\/\/www.uniprot.org\/uniprot\/Q16671, (accessed September 27, 2019)."},{"key":"10.1016\/j.smim.2020.101392_bib0095","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101392_bib0100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000129690","article-title":"Professor Alfred Jost: the builder of modern sex differentiation","volume":"2","author":"Josso","year":"2008","journal-title":"Sex. Dev."},{"key":"10.1016\/j.smim.2020.101392_bib0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4615-0621-8_3","article-title":"Mullerian inhibiting substance: an update","volume":"511","author":"MacLaughlin","year":"2002","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.smim.2020.101392_bib0110","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1093\/humrep\/deg507","article-title":"Evidence of apoptosis in human primordial and primary follicles","volume":"18","author":"Depalo","year":"2003","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.smim.2020.101392_bib0115","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2004.06.075","article-title":"Apoptosis and active caspase-3 expression in human granulosa cells","volume":"83","author":"Glamoclija","year":"2005","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.smim.2020.101392_bib0120","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.fertnstert.2007.03.066","article-title":"M\u00fcllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture","volume":"89","author":"Grossman","year":"2008","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.smim.2020.101392_bib0125","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.fertnstert.2013.04.019","article-title":"Antim\u00fcllerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells","volume":"100","author":"Chang","year":"2013","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.smim.2020.101392_bib0130","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10815-014-0328-7","article-title":"Is AMH a regulator of follicular atresia?","volume":"31","author":"Seifer","year":"2014","journal-title":"J. Assist. Reprod. Genet."},{"key":"10.1016\/j.smim.2020.101392_bib0135","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/labinvest.2011.116","article-title":"Anti-M\u00fcllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis","volume":"91","author":"Anttonen","year":"2011","journal-title":"Lab. Invest."},{"key":"10.1016\/j.smim.2020.101392_bib0140","first-page":"3260","article-title":"Anti-M\u00fcllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor","author":"Zhang","year":"2018","journal-title":"Oncol. Lett.16"},{"key":"10.1016\/j.smim.2020.101392_bib0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5468\/ogs.2014.57.5.343","article-title":"M\u00fcllerian inhibiting substance\/anti-M\u00fcllerian hormone: a novel treatment for gynecologic tumors","volume":"57","author":"Kim","year":"2014","journal-title":"Obstet. Gynecology. Sci."},{"key":"10.1016\/j.smim.2020.101392_bib0150","series-title":"SEER Cancer Statistics Review, 1975-2016","year":"2019"},{"key":"10.1016\/j.smim.2020.101392_bib0155","first-page":"7","article-title":"Cancer statistics, 2019","volume":"16","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.smim.2020.101392_bib0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2007.09.010","article-title":"M\u00fcllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers","volume":"108","author":"Bakkum-Gamez","year":"2008","journal-title":"Gynecology. Oncol."},{"key":"10.1016\/j.smim.2020.101392_bib0165","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1042\/bj20031961","article-title":"The anti-M\u00fcllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand","volume":"379","author":"Salhi","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.smim.2020.101392_bib0170","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1158\/1940-6207.CAPR-17-0154","article-title":"Primary immunoprevention of epithelial ovarian carcinoma by vaccination against the extracellular domain of anti-M\u00fcllerian hormone receptor II","volume":"10","author":"Mazumder","year":"2017","journal-title":"Cancer. Prev. Res. (Phila)."},{"key":"10.1016\/j.smim.2020.101392_bib0175","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nm.2161","article-title":"An autoimmune-mediated strategy for prophylactic breast cancer vaccination","volume":"16","author":"Jaini","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.smim.2020.101392_bib0180","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE, J. Natl","volume":"105","author":"Mavaddat","year":"2013","journal-title":"Cancer. Inst."},{"key":"10.1016\/j.smim.2020.101392_bib0185","first-page":"1","article-title":"Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know","volume":"90","author":"Franceschini","year":"2019","journal-title":"Ann. Ital. Chir."},{"key":"10.1016\/j.smim.2020.101392_bib0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-018-5057-7","article-title":"Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the inherited Cancer registry (ICARE)","volume":"174","author":"Henry","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"Jul 1","key":"10.1016\/j.smim.2020.101392_bib0195","article-title":"Risk-reducing surgery in BRCA1\/BRCA2 mutation carriers: are there factors associated with the choice?","author":"Manoukian","year":"2019","journal-title":"Psychooncology."},{"key":"10.1016\/j.smim.2020.101392_bib0200","series-title":"Cancer Facts & Figures 2019","author":"American Cancer Society","year":"2019"},{"key":"10.1016\/j.smim.2020.101392_bib0205","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/igc.0000000000001147","article-title":"Setting the threshold for surgical prevention in women at increased risk of ovarian cancer","volume":"28","author":"Manchanda","year":"2018","journal-title":"Int. J. Gynecology. Cancer."},{"key":"10.1016\/j.smim.2020.101392_bib0210","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ygyno.2015.06.020","article-title":"Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy","volume":"138","author":"Garcia","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.smim.2020.101392_bib0215","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/IGC.0000000000000943","article-title":"Review article: sexuality and risk-reducing salpingo-oophorectomy","volume":"27","author":"Tucker","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.smim.2020.101392_bib0220","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ygyno.2018.10.010","article-title":"Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations","volume":"151","author":"Powell","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.smim.2020.101392_bib0225","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/AOG.0000000000002285","article-title":"Practice Bulletin No. 182 Summary: hereditary breast and ovarian cancer syndrome","volume":"130","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.smim.2020.101392_bib0230","article-title":"Risk-reducing mastectomy for the prevention of primary breast cancer","volume":"4","author":"Carbine","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.smim.2020.101392_bib0235","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1245\/s10434-015-4715-9","article-title":"Chemoprevention for breast cancer","volume":"22","author":"Pruthi","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.smim.2020.101392_bib0240","article-title":"Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations","volume":"8","author":"Eleje","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.smim.2020.101392_bib0245","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1245\/s10434-019-07236-8","article-title":"Chemoprevention uptake for breast cancer risk reduction varies by risk factor","volume":"26","author":"Flanagan","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.smim.2020.101392_bib0250","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1158\/1055-9965.EPI-11-0650","article-title":"Economic burden of cancer in the United States: estimates, projections, and future research","volume":"20","author":"Yabroff","year":"2011","journal-title":"Cancer Epidemiol. Biomarkers Prev."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:16:17Z","timestamp":1760915777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532320300087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":50,"alternative-id":["S1044532320300087"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2020.101392","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary immunoprevention of adult onset cancers by vaccinating against retired tissue-specific self-proteins","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2020.101392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101392"}}